Traversa Therapeutics, Inc. and Sanofi-Aventis K.K. Enter into a Research Agreement for the Development of Traversa's RNAi Delivery Technology
3/25/2010 10:30:31 AM
SAN DIEGO--(BUSINESS WIRE)--Traversa Therapeutics announced today the signing of a research agreement with sanofi-aventis for the validation and development of Traversa’s RNAi delivery technology: PTD-DRBD. Under the agreement, the companies will study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
comments powered by